[HTML][HTML] Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
GJ Joseph, DB Johnson, RW Johnson - Journal of Bone Oncology, 2023 - Elsevier
Immune checkpoint inhibitors (ICIs) have revolutionized the field of anti-cancer therapy over
the last decade; they provide durable clinical responses against tumors by inhibiting …
the last decade; they provide durable clinical responses against tumors by inhibiting …
Multiple influence of immune cells in the bone metastatic cancer microenvironment on tumors
S Chen, J Lei, H Mou, W Zhang, L Jin, S Lu… - Frontiers in …, 2024 - frontiersin.org
Bone is a common organ for solid tumor metastasis. Malignant bone tumor becomes
insensitive to systemic therapy after colonization, followed by poor prognosis and high …
insensitive to systemic therapy after colonization, followed by poor prognosis and high …
Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis
BW Tian, CL Han, HC Wang, LJ Yan, ZN Ding… - Clinical & Experimental …, 2023 - Springer
Liver metastasis is a frequent phenomenon in advanced tumor disease. Immune checkpoint
inhibitors (ICIs) are a new class of therapeutics that can improve the prognosis of cancer …
inhibitors (ICIs) are a new class of therapeutics that can improve the prognosis of cancer …
Management of brain metastases in metastatic renal cell carcinoma
The presence of brain metastases is a poor prognostic feature in metastatic renal cell
carcinoma (mRCC) even in the era of immunotherapy. 1–3 In older studies of mRCC, brain …
carcinoma (mRCC) even in the era of immunotherapy. 1–3 In older studies of mRCC, brain …
Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review
J Brown, D Santini, N Charnley, A Ogareva… - Cancer Treatment …, 2024 - Elsevier
Introduction Bone metastases negatively affect prognosis in patients with advanced renal
cell carcinoma (aRCC). We conducted a systematic literature review to identify clinical trial …
cell carcinoma (aRCC). We conducted a systematic literature review to identify clinical trial …
[HTML][HTML] Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access …
Background The Meet-URO score allowed a more accurate prognostication than the
International Metastatic RCC Database Consortium (IMDC) for patients with pre-treated …
International Metastatic RCC Database Consortium (IMDC) for patients with pre-treated …
Changes in real-world outcomes in patients with metastatic renal cell carcinoma from the molecular-targeted therapy era to the immune checkpoint inhibitor era
H Ishihara, Y Nemoto, K Nakamura, H Tachibana… - Targeted Oncology, 2022 - Springer
Background Knowledge of changes in the outcome in patients with metastatic renal cell
carcinoma from the molecular-targeted therapy era to the immune checkpoint inhibitor (ICI) …
carcinoma from the molecular-targeted therapy era to the immune checkpoint inhibitor (ICI) …
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell …
A Samuelly, RF Di Stefano, F Turco… - Journal of Clinical …, 2024 - mdpi.com
The use of immune checkpoint inhibitors (ICIs) in combination with tyrosine kinase inhibitors
or other ICIs has significantly improved the prognosis for patients with mccRCC. This marks …
or other ICIs has significantly improved the prognosis for patients with mccRCC. This marks …
Comprehensive assessments of immuno‐oncology drug‐based combination therapies as first‐line treatment for advanced renal cell carcinoma
K Harada, H Miyake, J Furukawa… - … Journal of Urology, 2022 - Wiley Online Library
Over the last decade, there have been substantial progress in the field of systemic therapy
for advanced renal cell carcinoma. Through the transition from treatment with cytokines to …
for advanced renal cell carcinoma. Through the transition from treatment with cytokines to …
[HTML][HTML] Nivolumab–ipilimumab in renal cell carcinoma metastatic to the bones: A case report
M Di Napoli, C Pisano, SV Setola… - Acta Bio Medica …, 2022 - ncbi.nlm.nih.gov
In recent years, the introduction in the clinical setting of treatment combinations having
immune checkpoint inhibitors as the backbone has dramatically improved the outcomes of …
immune checkpoint inhibitors as the backbone has dramatically improved the outcomes of …